Zejula (Niraparibe Capsule) 100mg

ZEJULA (niraparib) capsules are a prescription PARP inhibitor used for ovarian cancer maintenance therapy. This 100mg strength formulation comes in a 56-count pack for convenient dosing. Ideal for targeted cancer support with ambient storage needs.

Strength

100mg

Pack Size

56s

Storage

Ambient

Manufacturer / TM Owner

GlaxoSmith Kline AG

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Niraparib is primarily used as maintenance treatment for recurrent ovarian cancer after response to platinum-based chemotherapy. It helps delay disease progression by inhibiting PARP enzymes, supporting DNA repair in cancer cells. Patients often ask what is niraparib used for, and it is indicated for epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Side Effects

Common effects of niraparib include mild nausea, fatigue, and digestive discomfort during the initial treatment phase. Some patients may experience temporary changes in blood cell counts, which are typically monitored through regular blood tests. These effects vary by individual and should be discussed with a healthcare provider.

Precautions & Warnings

Store niraparib capsules at room temperature away from moisture and direct light. Keep the medication in its original packaging until ready to use. Always handle with care and avoid crushing or splitting capsules to prevent exposure. Consult a healthcare professional if you have concerns about storage or handling.

Avoid Interactions

Niraparib may interact with strong CYP3A inhibitors or inducers, which can alter its effectiveness. Avoid grapefruit products and St. John’s wort while taking this medication. Alcohol use should be discussed with a doctor, as it may exacerbate certain side effects. Always inform your healthcare provider about all medications and supplements you are taking.

Frequently Asked Questions

Niraparib is used as maintenance therapy for recurrent ovarian cancer after platinum-based chemotherapy.

Store at room temperature in a dry place, away from light and moisture.

Consult your doctor before combining with other drugs, as interactions may occur.

Common effects include nausea, fatigue, and changes in blood cell counts.

No, it is a targeted therapy known as a PARP inhibitor, not a traditional chemotherapy agent.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 28 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.